Damien Freyssenet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Damien Freyssenet has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Josiane Castells
Laboratoire Interuniversitaire de Biologie de la Motricité Université Jean Monnet‐Saint‐Etienne Saint Etienne France
8 shared publicationsAnne-Cécile Durieux
Université de Lyon, Laboratoire Interuniversitaire de Biologie de la Motricité, Saint Etienne, F-42023, Lyon, France
5 shared publicationsAnne‐Cécile Durieux
Laboratoire Interuniversitaire de Biologie de la Motricité Université Jean Monnet Saint‐Etienne, Université Lyon 1, Université Savoie Mont‐Blanc Saint‐Etienne France
4 shared publicationsMarine Maud Desgeorges
Université de Lyon, Laboratoire Interuniversitaire de Biologie de la Motricité, Saint Etienne, F-42023, Lyon, France
4 shared publicationsRégis Bonnefoy
Université Jean Monnet
4 shared publicationsAgnès Martin
Laboratoire Interuniversitaire de Biologie de la Motricité EA 7424, Univ Lyon Université Jean Monnet Saint‐Etienne Saint‐Priest‐en‐Jarez France
3 shared publications
Latest Publications
- Open Access
Distinct iron metabolism regulation during cachexia progression in murine models of intestinal and pancreatic cancer
Background: Cancer cachexia is a multifactorial syndrome characterized by substantial metabolic disturbances including systemic inflammation, and muscle atrophy, which may affect the regulation of iron metabolism in patients. This study aimed to characterize this regulation in two murine models of colorectal and pancreatic cancer, both associated with a high prevalence of cachexia. Methods: Histological, biochemical and molecular analyses were performed in serum, skeletal muscle, liver, spleen and tumor from UN-KC-6141 pancreatic tumor bearing mice and from Apc Min/+ mice (colorectal cancer model), both models exhibiting variable cachexia severity. Results: Both models induce cachexia, but diverge markedly in their regulation of iron metabolism. UNKC mice display reduced plasma iron availability (-9.6% transferrin saturation, pApc Min/+ mice exhibit anemia together with hepatic and splenic iron depletion (-48.4%, pApc Min/+ mice, iron deficiency is associated with decreased FPN and ferritin (-87.9%, pApc Min/+ colorectal cancer model. In pancreatic cancer, hepatic hepcidin is upregulated, likely in response to inflammation, and induces splenic iron sequestration, resulting in decreased plasma iron availability. In colorectal cancer, cachexia is associated with anemia together with splenic and hepatic iron depletion, whose signals probably drive hepcidin downregulation despite inflammation. Whatever the model, skeletal muscle appears to engage cellular adaptive regulatory mechanisms to preserve itself from the systemic iron dysregulation induced by cancer cachexia and its associated features.
Open AccessDistinct iron metabolism regulation during cachexia progression in murine models of intestinal and pancreatic cancer
Background: Cancer cachexia is a multifactorial syndrome characterized by substantial metabolic disturbances including systemic inflammation, and muscle atrophy, which may affect the regulation of iron metabolism in patients. This study aimed to characterize this regulation in two murine models of colorectal and pancreatic cancer, both associated with a high prevalence of cachexia. Methods: Histological, biochemical and molecular analyses were performed in serum, skeletal muscle, liver, spleen and tumor from UN-KC-6141 pancreatic tumor bearing mice and from Apc Min/+ mice (colorectal cancer model), both models exhibiting variable cachexia severity. Results: Both models induce cachexia, but diverge markedly in their regulation of iron metabolism. UNKC mice display reduced plasma iron availability (-9.6% transferrin saturation, pApc Min/+ mice exhibit anemia together with hepatic and splenic iron depletion (-48.4%, pApc Min/+ mice, iron deficiency is associated with decreased FPN and ferritin (-87.9%, pApc Min/+ colorectal cancer model. In pancreatic cancer, hepatic hepcidin is upregulated, likely in response to inflammation, and induces splenic iron sequestration, resulting in decreased plasma iron availability. In colorectal cancer, cachexia is associated with anemia together with splenic and hepatic iron depletion, whose signals probably drive hepcidin downregulation despite inflammation. Whatever the model, skeletal muscle appears to engage cellular adaptive regulatory mechanisms to preserve itself from the systemic iron dysregulation induced by cancer cachexia and its associated features.
- Open Access
- 11 September 2026
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (5) , e70338
Genetic and Pharmacologic Inhibition of Myostatin Restores Muscle Mass in a Dynamin 2 ‐Related Centronuclear Myopathy Mouse Model
Background: Autosomal dominant centronuclear myopathy (ADCNM), most commonly caused by mutations in the dynamin 2 ( DNM2 ) gene, is a rare congenital myopathy characterized by progressive muscle weakness and atrophy. Myostatin, a key negative regulator of skeletal muscle mass, has shown therapeutic potential in several models of neuromuscular diseases. We hypothesized that inhibiting myostatin could counteract muscle deconditioning in ADCNM and evaluated the therapeutic potential of both genetic and pharmacological myostatin inhibition strategies in a mouse model of ADCNM. Methods: Knockin‐ dnm2 R465W/+ (KI) mice were first crossed with knockout‐ myostatin mice (KO) to generate double mutant (KIKO) mice carrying both the R465W missense mutation and the myostatin gene deletion. In a second experiment, KI mice received intraperitoneal injections of a soluble activin type IIB receptor fused to IgG1 Fc fragment (sActRIIB‐Fc) at 5 mg kg −1 twice weekly starting at 4 weeks of age for 4 weeks. Muscle structure, molecular pathways and functional analysis were performed in tibialis anterior muscle. Results: MRI and immunohistochemical analyses showed that KI mice exhibited impaired postnatal muscle growth between 1 and 2 months of age, resulting in persistent muscle hypotrophy (−15%, p < 0.05). This defect was associated with a significant reduction in the number of satellite cells (−53%, p < 0.001 at 1 month and −68%, p < 0.01 at 2 months), the central accumulation of dense NADH‐TR staining in more than 20% of muscle fibres, an upregulation of atrophy‐related E3 ligases mRNA ( Trim63 + 50%, p < 0.001 and +87%, p < 0.001 ; Fbxo32 + 39% p < 0.05 and +95%, p < 0.001 at 1 and 2 months of age, respectively) and impaired autophagy. Genetic deletion of myostatin in KIKO mice fully restored muscle mass and normalized muscle function to wild‐type conditions. Pharmacological inhibition with sActRIIB‐Fc also robustly restored muscle mass to wild‐type values, primarily via activation of the Akt–mTOR pathway. However, this anabolic effect was transient, as muscle mass returned to baseline 5 weeks after treatment cessation. Importantly, despite increased muscle mass, sActRIIB‐Fc treatment did not improve muscle force and key pathological features, including defects in proteostasis, mitochondrial organization and excitation‐contraction coupling. Conclusions: These findings establish the proof of concept that myostatin inhibition counteracts skeletal muscle growth defect in ADCNM, which may be combined with other drugs to better address the multifactorial nature of muscle weakness in ADCNM.
- 11 September 2026
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (5) , e70338
Open AccessGenetic and Pharmacologic Inhibition of Myostatin Restores Muscle Mass in a Dynamin 2 ‐Related Centronuclear Myopathy Mouse Model
Background: Autosomal dominant centronuclear myopathy (ADCNM), most commonly caused by mutations in the dynamin 2 ( DNM2 ) gene, is a rare congenital myopathy characterized by progressive muscle weakness and atrophy. Myostatin, a key negative regulator of skeletal muscle mass, has shown therapeutic potential in several models of neuromuscular diseases. We hypothesized that inhibiting myostatin could counteract muscle deconditioning in ADCNM and evaluated the therapeutic potential of both genetic and pharmacological myostatin inhibition strategies in a mouse model of ADCNM. Methods: Knockin‐ dnm2 R465W/+ (KI) mice were first crossed with knockout‐ myostatin mice (KO) to generate double mutant (KIKO) mice carrying both the R465W missense mutation and the myostatin gene deletion. In a second experiment, KI mice received intraperitoneal injections of a soluble activin type IIB receptor fused to IgG1 Fc fragment (sActRIIB‐Fc) at 5 mg kg −1 twice weekly starting at 4 weeks of age for 4 weeks. Muscle structure, molecular pathways and functional analysis were performed in tibialis anterior muscle. Results: MRI and immunohistochemical analyses showed that KI mice exhibited impaired postnatal muscle growth between 1 and 2 months of age, resulting in persistent muscle hypotrophy (−15%, p < 0.05). This defect was associated with a significant reduction in the number of satellite cells (−53%, p < 0.001 at 1 month and −68%, p < 0.01 at 2 months), the central accumulation of dense NADH‐TR staining in more than 20% of muscle fibres, an upregulation of atrophy‐related E3 ligases mRNA ( Trim63 + 50%, p < 0.001 and +87%, p < 0.001 ; Fbxo32 + 39% p < 0.05 and +95%, p < 0.001 at 1 and 2 months of age, respectively) and impaired autophagy. Genetic deletion of myostatin in KIKO mice fully restored muscle mass and normalized muscle function to wild‐type conditions. Pharmacological inhibition with sActRIIB‐Fc also robustly restored muscle mass to wild‐type values, primarily via activation of the Akt–mTOR pathway. However, this anabolic effect was transient, as muscle mass returned to baseline 5 weeks after treatment cessation. Importantly, despite increased muscle mass, sActRIIB‐Fc treatment did not improve muscle force and key pathological features, including defects in proteostasis, mitochondrial organization and excitation‐contraction coupling. Conclusions: These findings establish the proof of concept that myostatin inhibition counteracts skeletal muscle growth defect in ADCNM, which may be combined with other drugs to better address the multifactorial nature of muscle weakness in ADCNM.
- Open Access
- 25 October 2024
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 15 (6) , 2323-2337
Molecular determinants of skeletal muscle force loss in response to 5 days of dry immersion in human
Background: Astronauts in Earth's orbit experience microgravity, resulting in a decline of skeletal muscle mass and function. On Earth, models simulating microgravity have shown that the extent of the loss in muscle force is greater than the loss in muscle mass. The reasons behind this disproportionate loss of muscle force are still poorly understood. In the present study, we hypothesize that alongside the loss in skeletal muscle mass, modifications in the expression profile of genes encoding critical determinants of resting membrane potential, excitation‐contraction coupling and Ca2+ handling contribute to the decline in skeletal muscle force.Methods: Healthy male volunteers (n = 18) participated in a 5‐day dry immersion (DI) study, an Earth‐based model of simulated microgravity. Muscle force measurement and MRI analysis of the cross‐sectional area of thigh muscles were performed before and after DI. Biopsies of the vastus lateralis skeletal muscle performed before and after DI were used for the determination Ca2+ properties of isolated muscle fibres, molecular and biochemical analyses.Results: The extent of the decline in force, measured as maximal voluntary contraction of knee extensors (−11.1%, P < 0.01) was higher than the decline in muscle mass (−2.5%, P < 0.01). The decline in muscle mass was molecularly supported by a significant repression of the anabolic IGF‐1/Akt/mTOR pathway (−19.9% and −40.9% in 4E‐BP1 and RPS6 phosphorylation, respectively), a transcriptional downregulation of the autophagy‐lysosome pathway and a downregulation in the mRNA levels of myofibrillar protein slow isoforms. At the single fibre level, biochemical and tension‐pCa curve analyses showed that the loss in force was independent of fibre type (−11% and −12.3% in slow and fast fibres, respectively) and Ca2+ activation properties. Finally, we showed a significant remodelling in the expression of critical players of resting membrane potential (aquaporin 4: −24.9%, ATP1A2: +50.4%), excitation‐contraction coupling (CHRNA1: +75.1%, CACNA2D1: −23.5%, JPH2: −24.2%, TRDN: −15.6%, S100A1: +27.2%), and Ca2+ handling (ATP2A2: −32.5%, CASQ1: −15%, ORAI1: −36.2%, ATP2B1: −19.1%).Conclusions: These findings provide evidence that a deregulation in the expression profile of critical molecular determinants of resting membrane potential, excitation‐contraction coupling, and Ca2+ handling could be involved in the loss of muscle force induced by DI. They also provide the paradigm for the understanding of muscle force loss during prolonged bed rest periods as those encountered in intensive care unit.
- 25 October 2024
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 15 (6) , 2323-2337
Open AccessMolecular determinants of skeletal muscle force loss in response to 5 days of dry immersion in human
Background: Astronauts in Earth's orbit experience microgravity, resulting in a decline of skeletal muscle mass and function. On Earth, models simulating microgravity have shown that the extent of the loss in muscle force is greater than the loss in muscle mass. The reasons behind this disproportionate loss of muscle force are still poorly understood. In the present study, we hypothesize that alongside the loss in skeletal muscle mass, modifications in the expression profile of genes encoding critical determinants of resting membrane potential, excitation‐contraction coupling and Ca2+ handling contribute to the decline in skeletal muscle force.Methods: Healthy male volunteers (n = 18) participated in a 5‐day dry immersion (DI) study, an Earth‐based model of simulated microgravity. Muscle force measurement and MRI analysis of the cross‐sectional area of thigh muscles were performed before and after DI. Biopsies of the vastus lateralis skeletal muscle performed before and after DI were used for the determination Ca2+ properties of isolated muscle fibres, molecular and biochemical analyses.Results: The extent of the decline in force, measured as maximal voluntary contraction of knee extensors (−11.1%, P < 0.01) was higher than the decline in muscle mass (−2.5%, P < 0.01). The decline in muscle mass was molecularly supported by a significant repression of the anabolic IGF‐1/Akt/mTOR pathway (−19.9% and −40.9% in 4E‐BP1 and RPS6 phosphorylation, respectively), a transcriptional downregulation of the autophagy‐lysosome pathway and a downregulation in the mRNA levels of myofibrillar protein slow isoforms. At the single fibre level, biochemical and tension‐pCa curve analyses showed that the loss in force was independent of fibre type (−11% and −12.3% in slow and fast fibres, respectively) and Ca2+ activation properties. Finally, we showed a significant remodelling in the expression of critical players of resting membrane potential (aquaporin 4: −24.9%, ATP1A2: +50.4%), excitation‐contraction coupling (CHRNA1: +75.1%, CACNA2D1: −23.5%, JPH2: −24.2%, TRDN: −15.6%, S100A1: +27.2%), and Ca2+ handling (ATP2A2: −32.5%, CASQ1: −15%, ORAI1: −36.2%, ATP2B1: −19.1%).Conclusions: These findings provide evidence that a deregulation in the expression profile of critical molecular determinants of resting membrane potential, excitation‐contraction coupling, and Ca2+ handling could be involved in the loss of muscle force induced by DI. They also provide the paradigm for the understanding of muscle force loss during prolonged bed rest periods as those encountered in intensive care unit.
- Top Cited PapersOpen Access
- 2 March 2023
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 14 (3) , 1150-1167
Molecular mechanisms of cancer cachexia‐related loss of skeletal muscle mass: data analysis from preclinical and clinical studies
Cancer cachexia is a systemic hypoanabolic and catabolic syndrome that diminishes the quality of life of cancer patients, decreases the efficiency of therapeutic strategies and ultimately contributes to decrease their lifespan. The depletion of skeletal muscle compartment, which represents the primary site of protein loss during cancer cachexia, is of very poor prognostic in cancer patients. In this review, we provide an extensive and comparative analysis of the molecular mechanisms involved in the regulation of skeletal muscle mass in human cachectic cancer patients and in animal models of cancer cachexia. We summarize data from preclinical and clinical studies investigating how the protein turnover is regulated in cachectic skeletal muscle and question to what extent the transcriptional and translational capacities, as well as the proteolytic capacity (ubiquitin–proteasome system, autophagy–lysosome system and calpains) of skeletal muscle are involved in the cachectic syndrome in human and animals. We also wonder how regulatory mechanisms such as insulin/IGF1–AKT–mTOR pathway, endoplasmic reticulum stress and unfolded protein response, oxidative stress, inflammation (cytokines and downstream IL1ß/TNFα–NF‐κB and IL6–JAK–STAT3 pathways), TGF‐ß signalling pathways (myostatin/activin A‐SMAD2/3 and BMP‐SMAD1/5/8 pathways), as well as glucocorticoid signalling, modulate skeletal muscle proteostasis in cachectic cancer patients and animals. Finally, a brief description of the effects of various therapeutic strategies in preclinical models is also provided. Differences in the molecular and biochemical responses of skeletal muscle to cancer cachexia between human and animals (protein turnover rates, regulation of ubiquitin‐proteasome system and myostatin/activin A‐SMAD2/3 signalling pathways) are highlighted and discussed. Identifying the various and intertwined mechanisms that are deregulated during cancer cachexia and understanding why they are decontrolled will provide therapeutic targets for the treatment of skeletal muscle wasting in cancer patients.
- 2 March 2023
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 14 (3) , 1150-1167
Top Cited PapersOpen AccessMolecular mechanisms of cancer cachexia‐related loss of skeletal muscle mass: data analysis from preclinical and clinical studies
Cancer cachexia is a systemic hypoanabolic and catabolic syndrome that diminishes the quality of life of cancer patients, decreases the efficiency of therapeutic strategies and ultimately contributes to decrease their lifespan. The depletion of skeletal muscle compartment, which represents the primary site of protein loss during cancer cachexia, is of very poor prognostic in cancer patients. In this review, we provide an extensive and comparative analysis of the molecular mechanisms involved in the regulation of skeletal muscle mass in human cachectic cancer patients and in animal models of cancer cachexia. We summarize data from preclinical and clinical studies investigating how the protein turnover is regulated in cachectic skeletal muscle and question to what extent the transcriptional and translational capacities, as well as the proteolytic capacity (ubiquitin–proteasome system, autophagy–lysosome system and calpains) of skeletal muscle are involved in the cachectic syndrome in human and animals. We also wonder how regulatory mechanisms such as insulin/IGF1–AKT–mTOR pathway, endoplasmic reticulum stress and unfolded protein response, oxidative stress, inflammation (cytokines and downstream IL1ß/TNFα–NF‐κB and IL6–JAK–STAT3 pathways), TGF‐ß signalling pathways (myostatin/activin A‐SMAD2/3 and BMP‐SMAD1/5/8 pathways), as well as glucocorticoid signalling, modulate skeletal muscle proteostasis in cachectic cancer patients and animals. Finally, a brief description of the effects of various therapeutic strategies in preclinical models is also provided. Differences in the molecular and biochemical responses of skeletal muscle to cancer cachexia between human and animals (protein turnover rates, regulation of ubiquitin‐proteasome system and myostatin/activin A‐SMAD2/3 signalling pathways) are highlighted and discussed. Identifying the various and intertwined mechanisms that are deregulated during cancer cachexia and understanding why they are decontrolled will provide therapeutic targets for the treatment of skeletal muscle wasting in cancer patients.
- Open Access
- 11 March 2022
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 13 (3) , 1686-1703
Hypothalamic–pituitary–adrenal axis activation and glucocorticoid‐responsive gene expression in skeletal muscle and liver of Apc mice
Background: Cancer patients at advanced stages experience a severe depletion of skeletal muscle compartment together with a decrease in muscle function, known as cancer cachexia. Cachexia contributes to reducing quality of life, treatment efficiency, and lifespan of cancer patients. However, the systemic nature of the syndrome is poorly documented. Here, we hypothesize that glucocorticoids would be important systemic mediators of cancer cachexia.Methods: To explore the role of glucocorticoids during cancer cachexia, biomolecular analyses were performed on several tissues (adrenal glands, blood, hypothalamus, liver, and skeletal muscle) collected from ApcMin/+ male mice, a mouse model of intestine and colon cancer, aged of 13 and 23 weeks, and compared with wild type age‐matched C57BL/6J littermates.Results: Twenty‐three‐week‐old Apc mice recapitulated important features of cancer cachexia including body weight loss (−16%, P < 0.0001), muscle atrophy (gastrocnemius muscle: −53%, P < 0.0001), and weakness (−50% in tibialis anterior muscle force, P < 0.0001), increased expression of atrogens (7‐fold increase in MuRF1 transcript level, P < 0.0001) and down‐regulation of Akt–mTOR pathway (3.3‐fold increase in 4EBP1 protein content, P < 0.0001), together with a marked transcriptional rewiring of hepatic metabolism toward an increased expression of gluconeogenic genes (Pcx: +90%, Pck1: +85%), and decreased expression of glycolytic (Slc2a2: −40%, Gk: −30%, Pklr: −60%), ketogenic (Hmgcs2: −55%, Bdh1: −80%), lipolytic/fatty oxidation (Lipe: −50%, Mgll: −60%, Cpt2: −60%, Hadh: −30%), and lipogenic (Acly: −30%, Acacb: −70%, Fasn: −45%) genes. The hypothalamic pituitary–adrenal axis was activated, as evidenced by the increase in the transcript levels of genes encoding corticotropin‐releasing hormone in the hypothalamus (2‐fold increase, P < 0.01), adrenocorticotropic hormone receptor (3.4‐fold increase, P < 0.001), and steroid biosynthesis enzymes (Cyp21a1, P < 0.0001, and Cyp11b1, P < 0.01) in the adrenal glands, as well as by the increase in corticosterone level in the serum (+73%, P < 0.05), skeletal muscle (+17%, P < 0.001), and liver (+24%, P < 0.05) of cachectic 23‐week‐old Apc mice. A comparative transcriptional analysis with dexamethasone‐treated C57BL/6J mice indicated that the activation of the hypothalamic–pituitary–adrenal axis in 23‐week‐old ApcMin/+ mice was significantly associated with the transcription of glucocorticoid‐responsive genes in skeletal muscle (P < 0.05) and liver (P < 0.001). The transcriptional regulation of glucocorticoid‐responsive genes was also observed in the gastrocnemius muscle of Lewis lung carcinoma tumour‐bearing mice and in KPC mice (tibialis anterior muscle and liver).Conclusions: These findings highlight the role of the hypothalamic–pituitary–adrenal‐glucocorticoid pathway in the transcriptional regulation of skeletal muscle catabolism and hepatic metabolism during cancer cachexia. They also provide the paradigm for the design of new therapeutic strategies.
- 11 March 2022
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 13 (3) , 1686-1703
Open AccessHypothalamic–pituitary–adrenal axis activation and glucocorticoid‐responsive gene expression in skeletal muscle and liver of Apc mice
Background: Cancer patients at advanced stages experience a severe depletion of skeletal muscle compartment together with a decrease in muscle function, known as cancer cachexia. Cachexia contributes to reducing quality of life, treatment efficiency, and lifespan of cancer patients. However, the systemic nature of the syndrome is poorly documented. Here, we hypothesize that glucocorticoids would be important systemic mediators of cancer cachexia.Methods: To explore the role of glucocorticoids during cancer cachexia, biomolecular analyses were performed on several tissues (adrenal glands, blood, hypothalamus, liver, and skeletal muscle) collected from ApcMin/+ male mice, a mouse model of intestine and colon cancer, aged of 13 and 23 weeks, and compared with wild type age‐matched C57BL/6J littermates.Results: Twenty‐three‐week‐old Apc mice recapitulated important features of cancer cachexia including body weight loss (−16%, P < 0.0001), muscle atrophy (gastrocnemius muscle: −53%, P < 0.0001), and weakness (−50% in tibialis anterior muscle force, P < 0.0001), increased expression of atrogens (7‐fold increase in MuRF1 transcript level, P < 0.0001) and down‐regulation of Akt–mTOR pathway (3.3‐fold increase in 4EBP1 protein content, P < 0.0001), together with a marked transcriptional rewiring of hepatic metabolism toward an increased expression of gluconeogenic genes (Pcx: +90%, Pck1: +85%), and decreased expression of glycolytic (Slc2a2: −40%, Gk: −30%, Pklr: −60%), ketogenic (Hmgcs2: −55%, Bdh1: −80%), lipolytic/fatty oxidation (Lipe: −50%, Mgll: −60%, Cpt2: −60%, Hadh: −30%), and lipogenic (Acly: −30%, Acacb: −70%, Fasn: −45%) genes. The hypothalamic pituitary–adrenal axis was activated, as evidenced by the increase in the transcript levels of genes encoding corticotropin‐releasing hormone in the hypothalamus (2‐fold increase, P < 0.01), adrenocorticotropic hormone receptor (3.4‐fold increase, P < 0.001), and steroid biosynthesis enzymes (Cyp21a1, P < 0.0001, and Cyp11b1, P < 0.01) in the adrenal glands, as well as by the increase in corticosterone level in the serum (+73%, P < 0.05), skeletal muscle (+17%, P < 0.001), and liver (+24%, P < 0.05) of cachectic 23‐week‐old Apc mice. A comparative transcriptional analysis with dexamethasone‐treated C57BL/6J mice indicated that the activation of the hypothalamic–pituitary–adrenal axis in 23‐week‐old ApcMin/+ mice was significantly associated with the transcription of glucocorticoid‐responsive genes in skeletal muscle (P < 0.05) and liver (P < 0.001). The transcriptional regulation of glucocorticoid‐responsive genes was also observed in the gastrocnemius muscle of Lewis lung carcinoma tumour‐bearing mice and in KPC mice (tibialis anterior muscle and liver).Conclusions: These findings highlight the role of the hypothalamic–pituitary–adrenal‐glucocorticoid pathway in the transcriptional regulation of skeletal muscle catabolism and hepatic metabolism during cancer cachexia. They also provide the paradigm for the design of new therapeutic strategies.
- Open Access
- 8 November 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 12064
Early Deconditioning of Human Skeletal Muscles and the Effects of a Thigh Cuff Countermeasure
Muscle deconditioning is a major consequence of a wide range of conditions from spaceflight to a sedentary lifestyle, and occurs as a result of muscle inactivity, leading to a rapid decrease in muscle strength, mass, and oxidative capacity. The early changes that appear in the first days of inactivity must be studied to determine effective methods for the prevention of muscle deconditioning. To evaluate the mechanisms of muscle early changes and the vascular effect of a thigh cuff, a five-day dry immersion (DI) experiment was conducted by the French Space Agency at the MEDES Space Clinic (Rangueil, Toulouse). Eighteen healthy males were recruited and divided into a control group and a thigh cuff group, who wore a thigh cuff at 30 mmHg. All participants underwent five days of DI. Prior to and at the end of the DI, the lower limb maximal strength was measured and muscle biopsies were collected from the vastus lateralis muscle. Five days of DI resulted in muscle deconditioning in both groups. The maximal voluntary isometric contraction of knee extension decreased significantly. The muscle fiber cross-sectional area decreased significantly by 21.8%, and the protein balance seems to be impaired, as shown by the reduced activation of the mTOR pathway. Measurements of skinned muscle fibers supported these results and potential changes in oxidative capacity were highlighted by a decrease in PGC1-α levels. The use of the thigh cuff did not prevent muscle deconditioning or impact muscle function. These results suggest that the major effects of muscle deconditioning occur during the first few days of inactivity, and countermeasures against muscle deconditioning should target this time period. These results are also relevant for the understanding of muscle weakness induced by muscle diseases, aging, and patients in intensive care.
- 8 November 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 12064
Open AccessEarly Deconditioning of Human Skeletal Muscles and the Effects of a Thigh Cuff Countermeasure
Muscle deconditioning is a major consequence of a wide range of conditions from spaceflight to a sedentary lifestyle, and occurs as a result of muscle inactivity, leading to a rapid decrease in muscle strength, mass, and oxidative capacity. The early changes that appear in the first days of inactivity must be studied to determine effective methods for the prevention of muscle deconditioning. To evaluate the mechanisms of muscle early changes and the vascular effect of a thigh cuff, a five-day dry immersion (DI) experiment was conducted by the French Space Agency at the MEDES Space Clinic (Rangueil, Toulouse). Eighteen healthy males were recruited and divided into a control group and a thigh cuff group, who wore a thigh cuff at 30 mmHg. All participants underwent five days of DI. Prior to and at the end of the DI, the lower limb maximal strength was measured and muscle biopsies were collected from the vastus lateralis muscle. Five days of DI resulted in muscle deconditioning in both groups. The maximal voluntary isometric contraction of knee extension decreased significantly. The muscle fiber cross-sectional area decreased significantly by 21.8%, and the protein balance seems to be impaired, as shown by the reduced activation of the mTOR pathway. Measurements of skinned muscle fibers supported these results and potential changes in oxidative capacity were highlighted by a decrease in PGC1-α levels. The use of the thigh cuff did not prevent muscle deconditioning or impact muscle function. These results suggest that the major effects of muscle deconditioning occur during the first few days of inactivity, and countermeasures against muscle deconditioning should target this time period. These results are also relevant for the understanding of muscle weakness induced by muscle diseases, aging, and patients in intensive care.
- Open Access
- 30 March 2021
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 12 (2) , 252-273
Phenotypic features of cancer cachexia‐related loss of skeletal muscle mass and function: lessons from human and animal studies
Cancer cachexia is a complex multi‐organ catabolic syndrome that reduces mobility, increases fatigue, decreases the efficiency of therapeutic strategies, diminishes the quality of life, and increases the mortality of cancer patients. This review provides an exhaustive and comprehensive analysis of cancer cachexia‐related phenotypic changes in skeletal muscle at both the cellular and subcellular levels in human cancer patients, as well as in animal models of cancer cachexia. Cancer cachexia is characterized by a major decrease in skeletal muscle mass in human and animals that depends on the severity of the disease/model and the localization of the tumour. It affects both type 1 and type 2 muscle fibres, even if some animal studies suggest that type 2 muscle fibres would be more prone to atrophy. Animal studies indicate an impairment in mitochondrial oxidative metabolism resulting from a decrease in mitochondrial content, an alteration in mitochondria morphology, and a reduction in mitochondrial metabolic fluxes. Immuno‐histological analyses in human and animal models also suggest that a faulty mechanism of skeletal muscle repair would contribute to muscle mass loss. An increase in collagen deposit, an accumulation of fat depot outside and inside the muscle fibre, and a disrupted contractile machinery structure are also phenotypic features that have been consistently reported in cachectic skeletal muscle. Muscle function is also profoundly altered during cancer cachexia with a strong reduction in skeletal muscle force. Even though the loss of skeletal muscle mass largely contributes to the loss of muscle function, other factors such as muscle–nerve interaction and calcium handling are probably involved in the decrease in muscle force. Longitudinal analyses of skeletal muscle mass by imaging technics and skeletal muscle force in cancer patients, but also in animal models of cancer cachexia, are necessary to determine the respective kinetics and functional involvements of these factors. Our analysis also emphasizes that measuring skeletal muscle force through standardized tests could provide a simple and robust mean to early diagnose cachexia in cancer patients. That would be of great benefit to cancer patient's quality of life and health care systems.
- 30 March 2021
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 12 (2) , 252-273
Open AccessPhenotypic features of cancer cachexia‐related loss of skeletal muscle mass and function: lessons from human and animal studies
Cancer cachexia is a complex multi‐organ catabolic syndrome that reduces mobility, increases fatigue, decreases the efficiency of therapeutic strategies, diminishes the quality of life, and increases the mortality of cancer patients. This review provides an exhaustive and comprehensive analysis of cancer cachexia‐related phenotypic changes in skeletal muscle at both the cellular and subcellular levels in human cancer patients, as well as in animal models of cancer cachexia. Cancer cachexia is characterized by a major decrease in skeletal muscle mass in human and animals that depends on the severity of the disease/model and the localization of the tumour. It affects both type 1 and type 2 muscle fibres, even if some animal studies suggest that type 2 muscle fibres would be more prone to atrophy. Animal studies indicate an impairment in mitochondrial oxidative metabolism resulting from a decrease in mitochondrial content, an alteration in mitochondria morphology, and a reduction in mitochondrial metabolic fluxes. Immuno‐histological analyses in human and animal models also suggest that a faulty mechanism of skeletal muscle repair would contribute to muscle mass loss. An increase in collagen deposit, an accumulation of fat depot outside and inside the muscle fibre, and a disrupted contractile machinery structure are also phenotypic features that have been consistently reported in cachectic skeletal muscle. Muscle function is also profoundly altered during cancer cachexia with a strong reduction in skeletal muscle force. Even though the loss of skeletal muscle mass largely contributes to the loss of muscle function, other factors such as muscle–nerve interaction and calcium handling are probably involved in the decrease in muscle force. Longitudinal analyses of skeletal muscle mass by imaging technics and skeletal muscle force in cancer patients, but also in animal models of cancer cachexia, are necessary to determine the respective kinetics and functional involvements of these factors. Our analysis also emphasizes that measuring skeletal muscle force through standardized tests could provide a simple and robust mean to early diagnose cachexia in cancer patients. That would be of great benefit to cancer patient's quality of life and health care systems.
- Open Access
- 25 October 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-11
Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke
In stroke patients, loss of skeletal muscle mass leads to prolonged weakness and less efficient rehabilitation. We previously showed that expression of myostatin, a master negative regulator of skeletal muscle mass, was strongly increased in skeletal muscle in a mouse model of stroke. We therefore tested the hypothesis that myostatin inhibition would improve recovery of skeletal muscle mass and function after cerebral ischemia. Cerebral ischemia (45 minutes) was induced by intraluminal right middle cerebral artery occlusion (MCAO). Swiss male mice were randomly assigned to Sham-operated mice (n = 10), MCAO mice receiving the vehicle (n = 15) and MCAO mice receiving an anti-myostatin PINTA745 (n = 12; subcutaneous injection of 7.5 mg.kg−1 PINTA745 immediately after surgery, 3, 7 and 10 days after MCAO). PINTA745 reduced body weight loss and improved body weight recovery after cerebral ischemia, as well as muscle strength and motor function. PINTA745 also increased muscle weight recovery 15 days after cerebral ischemia. Mechanistically, the better recovery of skeletal muscle mass in PINTA745-MCAO mice involved an increased expression of genes encoding myofibrillar proteins. Therefore, an anti-myostatin strategy can improve skeletal muscle recovery after cerebral ischemia and may thus represent an interesting strategy to combat skeletal muscle loss and weakness in stroke patients.
- 25 October 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-11
Open AccessPharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke
In stroke patients, loss of skeletal muscle mass leads to prolonged weakness and less efficient rehabilitation. We previously showed that expression of myostatin, a master negative regulator of skeletal muscle mass, was strongly increased in skeletal muscle in a mouse model of stroke. We therefore tested the hypothesis that myostatin inhibition would improve recovery of skeletal muscle mass and function after cerebral ischemia. Cerebral ischemia (45 minutes) was induced by intraluminal right middle cerebral artery occlusion (MCAO). Swiss male mice were randomly assigned to Sham-operated mice (n = 10), MCAO mice receiving the vehicle (n = 15) and MCAO mice receiving an anti-myostatin PINTA745 (n = 12; subcutaneous injection of 7.5 mg.kg−1 PINTA745 immediately after surgery, 3, 7 and 10 days after MCAO). PINTA745 reduced body weight loss and improved body weight recovery after cerebral ischemia, as well as muscle strength and motor function. PINTA745 also increased muscle weight recovery 15 days after cerebral ischemia. Mechanistically, the better recovery of skeletal muscle mass in PINTA745-MCAO mice involved an increased expression of genes encoding myofibrillar proteins. Therefore, an anti-myostatin strategy can improve skeletal muscle recovery after cerebral ischemia and may thus represent an interesting strategy to combat skeletal muscle loss and weakness in stroke patients.
- 1 June 2015
- Published by Wolters Kluwer Health in Stroke
- Vol. 46 (6) , 1673-1680
Molecular Mechanisms of Skeletal Muscle Atrophy in a Mouse Model of Cerebral Ischemia
Background and Purpose—: Loss of muscle mass and function is a severe complication in patients with stroke that contributes to promoting physical inactivity and disability. The deleterious consequences of skeletal muscle mass loss underline the necessity to identity the molecular mechanisms involved in skeletal muscle atrophy after cerebral ischemia. Methods—: Transient focal cerebral ischemia (60 minutes) was induced by occlusion of the right middle cerebral artery in C57BL/6J male mice. Skeletal muscles were removed 3 days later and analyzed for the regulation of critical determinants of muscle mass homeostasis (Akt/mammalian target of rapamycin pathway, myostatin-Smad2/3 and bone morphogenetic protein-Smad1/5/8 signaling pathways, ubiquitin-proteasome and autophagy-lysosome proteolytic pathways). Results—: Cerebral ischemia induced severe sensorimotor deficits associated with muscle mass loss of the paretic limbs. Mechanistically, cerebral ischemia repressed Akt/mammalian target of rapamycin pathway and increased expression of key players of ubiquitin-proteasome pathway (MuRF1 [muscle RING finger-1], MAFbx [muscle atrophy F-box], Musa1 [muscle ubiquitin ligase of SCF complex in atrophy-1]), together with a marked increase in myostatin expression, in both paretic and nonparetic skeletal muscles. The Smad1/5/8 pathway was also activated. Conclusions—: Our data fit with a model in which a repression of Akt/mammalian target of rapamycin pathway and an increase in the expression of key players of ubiquitin-proteasome pathway are critically involved in skeletal muscle atrophy after cerebral ischemia. Cerebral ischemia also caused an activation of bone morphogenetic protein-Smad1/5/8 signaling pathway, suggesting that compensatory mechanisms are also concomitantly activated to limit the extent of skeletal muscle atrophy.
- 1 June 2015
- Published by Wolters Kluwer Health in Stroke
- Vol. 46 (6) , 1673-1680
Molecular Mechanisms of Skeletal Muscle Atrophy in a Mouse Model of Cerebral Ischemia
Background and Purpose—: Loss of muscle mass and function is a severe complication in patients with stroke that contributes to promoting physical inactivity and disability. The deleterious consequences of skeletal muscle mass loss underline the necessity to identity the molecular mechanisms involved in skeletal muscle atrophy after cerebral ischemia. Methods—: Transient focal cerebral ischemia (60 minutes) was induced by occlusion of the right middle cerebral artery in C57BL/6J male mice. Skeletal muscles were removed 3 days later and analyzed for the regulation of critical determinants of muscle mass homeostasis (Akt/mammalian target of rapamycin pathway, myostatin-Smad2/3 and bone morphogenetic protein-Smad1/5/8 signaling pathways, ubiquitin-proteasome and autophagy-lysosome proteolytic pathways). Results—: Cerebral ischemia induced severe sensorimotor deficits associated with muscle mass loss of the paretic limbs. Mechanistically, cerebral ischemia repressed Akt/mammalian target of rapamycin pathway and increased expression of key players of ubiquitin-proteasome pathway (MuRF1 [muscle RING finger-1], MAFbx [muscle atrophy F-box], Musa1 [muscle ubiquitin ligase of SCF complex in atrophy-1]), together with a marked increase in myostatin expression, in both paretic and nonparetic skeletal muscles. The Smad1/5/8 pathway was also activated. Conclusions—: Our data fit with a model in which a repression of Akt/mammalian target of rapamycin pathway and an increase in the expression of key players of ubiquitin-proteasome pathway are critically involved in skeletal muscle atrophy after cerebral ischemia. Cerebral ischemia also caused an activation of bone morphogenetic protein-Smad1/5/8 signaling pathway, suggesting that compensatory mechanisms are also concomitantly activated to limit the extent of skeletal muscle atrophy.
- 14 December 2014
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (24) , 7344-7356
Myostatin Gene Inactivation Prevents Skeletal Muscle Wasting in Cancer
Cachexia is a muscle-wasting syndrome that contributes significantly to morbidity and mortality of many patients with advanced cancers. However, little is understood about how the severe loss of skeletal muscle characterizing this condition occurs. In the current study, we tested the hypothesis that the muscle protein myostatin is involved in mediating the pathogenesis of cachexia-induced muscle wasting in tumor-bearing mice. Myostatin gene inactivation prevented the severe loss of skeletal muscle mass induced in mice engrafted with Lewis lung carcinoma (LLC) cells or in ApcMin/+ mice, an established model of colorectal cancer and cachexia. Mechanistically, myostatin loss attenuated the activation of muscle fiber proteolytic pathways by inhibiting the expression of atrophy-related genes, MuRF1 and MAFbx/Atrogin-1, along with autophagy-related genes. Notably, myostatin loss also impeded the growth of LLC tumors, the number and the size of intestinal polyps in ApcMin/+ mice, thus strongly increasing survival in both models. Gene expression analysis in the LLC model showed this phenotype to be associated with reduced expression of genes involved in tumor metabolism, activin signaling, and apoptosis. Taken together, our results reveal an essential role for myostatin in the pathogenesis of cancer cachexia and link this condition to tumor growth, with implications for furthering understanding of cancer as a systemic disease. Cancer Res; 74(24); 7344–56. ©2014 AACR.
- 14 December 2014
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (24) , 7344-7356
Myostatin Gene Inactivation Prevents Skeletal Muscle Wasting in Cancer
Cachexia is a muscle-wasting syndrome that contributes significantly to morbidity and mortality of many patients with advanced cancers. However, little is understood about how the severe loss of skeletal muscle characterizing this condition occurs. In the current study, we tested the hypothesis that the muscle protein myostatin is involved in mediating the pathogenesis of cachexia-induced muscle wasting in tumor-bearing mice. Myostatin gene inactivation prevented the severe loss of skeletal muscle mass induced in mice engrafted with Lewis lung carcinoma (LLC) cells or in ApcMin/+ mice, an established model of colorectal cancer and cachexia. Mechanistically, myostatin loss attenuated the activation of muscle fiber proteolytic pathways by inhibiting the expression of atrophy-related genes, MuRF1 and MAFbx/Atrogin-1, along with autophagy-related genes. Notably, myostatin loss also impeded the growth of LLC tumors, the number and the size of intestinal polyps in ApcMin/+ mice, thus strongly increasing survival in both models. Gene expression analysis in the LLC model showed this phenotype to be associated with reduced expression of genes involved in tumor metabolism, activin signaling, and apoptosis. Taken together, our results reveal an essential role for myostatin in the pathogenesis of cancer cachexia and link this condition to tumor growth, with implications for furthering understanding of cancer as a systemic disease. Cancer Res; 74(24); 7344–56. ©2014 AACR.